625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update.
Saved in:
| Title: | 625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. |
|---|---|
| Authors: | Mourey, L.1 (AUTHOR), Conter, H.J.2 (AUTHOR), Shore, N.3 (AUTHOR), Berry, W.R.4 (AUTHOR), Fong, P.C.5 (AUTHOR), Piulats, J.M.6 (AUTHOR), Appleman, L.J.7 (AUTHOR), Todenhöfer, T.8 (AUTHOR), Gravis, G.9 (AUTHOR), Laguerre, B.10 (AUTHOR), Gurney, H.11 (AUTHOR), Retz, M.12 (AUTHOR), Romano, E.13 (AUTHOR), de Bono, J.S.14 (AUTHOR), Kam, A.E.15 (AUTHOR), Emmenegger, U.16 (AUTHOR), Wu, H.17 (AUTHOR), Qiu, P.17 (AUTHOR), Schloss, C.17 (AUTHOR), Yu, E.Y.18 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS516-S517. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.884 |
